Ace the CRNI Challenge 2026 – Infuse Your Career with Success!

The target absolute neutrophil count (ANC) that Neupogen (filgrastim) is aimed at is 10,000 cells/mm³. Neupogen is a granulocyte colony-stimulating factor that stimulates the production of neutrophils in the bone marrow, helping to prevent or treat neutropenia, particularly in patients undergoing chemotherapy.

The goal of using Neupogen is to reduce the risk of infection by ensuring that the neutrophil count reaches a safe and adequate level, thereby improving the patient's immune response. A target ANC of 10,000 reflects a sufficient level to effectively combat infections while minimizing any potential complications related to excessively high neutrophil counts, which could potentially lead to adverse effects or unnecessary strain on the body.

Understanding the appropriate target ANC is crucial for nurses and healthcare providers in managing patients who are at risk for neutropenia, particularly in oncology settings.